DelveInsight's Asthma Market Insights report includes a comprehensive understanding of current treatment practices, asthma emerging ...

Gavin Herbert is winning converts to his latest venture, which is trying to solve Long Covid.The founder of Allergan is ...

DelveInsight's GLP-1 Agonists Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

An unmet need exists for effective therapies to lower triglyceride levels in patients with residual cardiovascular risk despite optimal lipid-lowering therapies.     The ESSENCE-TIMI 73b trial ...

The University of Michigan has sued pharmaceutical giant AstraZeneca, alleging the company is still using the university's intellectual property in FluMist two years after the licensing agreement ...

- Joe Monahan, Ph.D. will Continue to Support Aclaris as Special Scientific Advisor to the Chief Executive Officer through March 2026 as Part of Planned Retirement - WAYNE, Pa., July 28, 2025 (GLOBE ...

Heather McArthur, MD, looks forward to ASCO 2025, where several pivotal studies in breast cancer will be presented. Key highlights include the DESTINY-Breast09 trial, which showed a significant ...

AstraZeneca has axed three MedImmune legacy monoclonal antibody drugs from its neuroscience pipeline in a first-quarter clear-out. The Anglo-Swedish Big Pharma announced in its first-quarter ...

In advanced NSCLC after chemotherapy progression, plasma-detected SGVs are common, and associated with inferior OS. Plasma SGV status should be considered as a stratification factor in future trials.

Alteogen Inc. signed its first billion-dollar partnership this year for ALT-B4 technology through two separate contracts with Astrazeneca plc’s U.K.- and U.S.-based Medimmune subsidiaries worth up to ...

Kiniksa Pharmaceuticals is stopping development of a midphase autoimmune asset and returning a drug candidate to AstraZeneca as it doubles down on its cardiovascular disease pipeline. The asset ...